| 06th week of 2017 patent applcation highlights part 8 |
| Patent application number | Title | Published |
|---|
| 20170035686 | PERSONAL CARE COMPOSITIONS - The invention relates to a personal care composition which provides enhanced inter- cellular tight junction in skin cells. The invention more particularly relates to use of such composition for application on skin, scalp, hair and oral cavity. The personal care composition comprises an extract of Aloe vera and a hyaluronic acid polymer having a molecular weight from 5 to 60 kDa. | 2017-02-09 |
| 20170035687 | Skin treatment formulations - Dermal treatment compositions include medium recovered from an adipose-derived stem cell culture where the medium is collected under defined conditions. The medium includes growth factors and other materials that, when transported to living portions of the skin, improve the condition of damaged or aged skin. The compositions include combinations of transport ingredients in controlled proportions for effective topical application. | 2017-02-09 |
| 20170035688 | TRANSMUCOSAL DRUG DELIVERY DEVICES FOR USE IN CHRONIC PAIN RELIEF - Provided herein are methods for treating chronic pain by administering low doses of buprenorphine twice daily (or once daily) via a transmucosal drug delivery device. The methods and devices efficiently treat chronic pain without significant side effects. | 2017-02-09 |
| 20170035689 | SUBLINGUAL AND BUCCAL FILM COMPOSITIONS - The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent. | 2017-02-09 |
| 20170035690 | Bioerodible Silicon-Based Devices for Delivery of Therapeutic Agents - This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases. | 2017-02-09 |
| 20170035691 | FOOD MATRICES AND METHODS OF MAKING AND USING - A method of these teachings for designing foods in order to improve the bioavailability of orally administered bioactive agents, the method including designing a food matrix, the food matrix not having bioactivity above its normal nutritional function, that increases bioavailability of a predetermined pharmaceutical or nutraceutical by at least one of facilitating the release and solubilization of bioactive agents in the predetermined pharmaceutical or nutraceutical, altering the absorption of lipophilic bioactive agents in the predetermined pharmaceutical or nutraceutical when co-ingested, or interfering with chemical transformations that occur within gastrointestinal tract (GIT) or after absorption; the food matrix being co-ingested with the predetermined pharmaceutical or nutraceutical or ingested at a specified time soon before or after the pharmaceutical or nutraceutical. | 2017-02-09 |
| 20170035692 | SELF-SUPPORTING FILMS FOR PHARMACEUTICAL AND FOOD USE - Rapidly dissolving self-supporting films for food or pharmaceutical use comprising: a) a filmogenic substance consisting of a maltodextrin; b) a plasticizer; c) an active principle for food or pharmaceutical use, characterized in that said films are free of hydrocolloids. | 2017-02-09 |
| 20170035693 | Sterile Emulsion Comprising a Stable Phosphorothioate Oligonucleotide - The present invention relates to a composition comprising a phosphorothioate oligonucleotide and at least one fatty acid and/or at least one emulsifying agent, wherein said composition is sterile and wherein said composition comprises an agent comprising a thiol group, preferably said composition is an ophthalmic composition; to a method for obtaining the same and to the therapeutic use thereof. | 2017-02-09 |
| 20170035694 | THERAPEUTIC POLYMERIC NANOPARTICLES COMPRISING CORTICOSTEROIDS AND METHODS OF MAKING AND USING SAME - The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.1 to about 50 weight percent of a corticosteroid; and about 50 to about 99 weight percent biocompatible polymer. | 2017-02-09 |
| 20170035695 | NOVEL CONTROLLED RELEASE COMPOSITION - The present disclosure provides a controlled release composition comprising a plurality of microparticles and a matrix, wherein: the plurality of microparticles comprises a first material; the matrix comprises a second material; and the melting temperature of the first material is higher than the melting temperature of the second material. Also provided are methods of making and using the same. | 2017-02-09 |
| 20170035696 | Composition of analgesic bioadhesive healing microspheres - A new composition of analgesic bioadhesive healing microspheres in which each microsphere comprises at least: | 2017-02-09 |
| 20170035697 | IMMEDIATE RELEASE FILM COATINGS CONTAINING MEDIUM CHAIN GLYCERIDES AND SUBSTRATES COATED THEREWITH - The present invention is directed to immediate release film coating compositions for use on oral dosage forms such as compressed tablets and other orally-ingestible substrates which contain medium chain glycerides as detackifiers. The film coating compositions can be applied either directly to a substrate or after the substrate has been coated with a subcoat. In preferred aspects, the polymer is polyvinyl alcohol and the medium chain glycerides are mixtures of caprylic (8 carbon chain) and capric (10 carbon chain) mono- and diesters of glycerin. Aqueous suspensions comprising the inventive film coating compositions, methods of applying the coatings to substrates and the coated substrates themselves are also disclosed. | 2017-02-09 |
| 20170035698 | DELAYED RELEASE DRUG FORMULATION - In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base. | 2017-02-09 |
| 20170035699 | ACID RESISTANT BANDING SOLUTION FOR ACID RESISTANT TWO PIECE HARD CAPSULES - The present disclosure relates to acid resistant banding solutions for two piece hard capsules endowed with acid resistant properties, and methods of making and using acid resistant banding solutions. The present disclosure also relates, in part, to methods for banding such acid resistant capsules which provides an acid resistant seal between the capsule parts and achieves increased acid resistance in vitro. | 2017-02-09 |
| 20170035700 | COATED EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS AND METHODS FOR USING THE SAME - Compositions are provided that comprise a microvesicle derived from an edible plant. The microvesicles are coated with a plasma membrane derived from a targeting cell and can further be utilized to encapsulate a therapeutic agent. Methods for treating an inflammatory disorder and/or a cancer are further provided and include the step of administering to a subject an effective amount of a composition that includes a microvesicle coated with a plasma membrane derived from a targeting cell. | 2017-02-09 |
| 20170035701 | STABILIZED HIGH DRUG LOAD NANOCARRIERS, METHODS FOR THEIR PREPARATION AND USE THEREOF - The present invention relates to generally to pharmaceutical formulations. Particularly, the present invention relates to a drug nanocarrier that is stabilized by lipids, preferably lecithins and/or lipid-terminated polyalkylene glycol, for the delivery of poorly soluble drugs with high drug loading and its utility in the fields of pharmaceutical formulation, drug delivery, medicine and diagnosis. | 2017-02-09 |
| 20170035702 | COMPOSITIONS AND METHODS FOR DELIVERY OF KINASE INHIBITING PEPTIDES - The invention relates to compositions and methods for the treatment of inflammatory disease states. In particular, the invention relates to the use of a nanoparticle incorporated kinase inhibiting peptide to treat inflammatory disease states. | 2017-02-09 |
| 20170035703 | Method of Treating Adhesion by Altering an Epithelial to Mesenchymal Transition - The present invention is a method of treating adhesion including the prevention or reduction of abdominal, pelvic, and thoracic adhesions, by administering an Epithelial-to-mesenchymal transition altering compound or device. The device may take the form of a substrate coated with an Epithelial-to-mesenchymal transition altering compound. | 2017-02-09 |
| 20170035704 | Composition for the Transdermal Delivery of Fentanyl - A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery device for the delivery of fentanyl. | 2017-02-09 |
| 20170035705 | DETRUSOR HYPERACTIVITY WITH IMPAIRED CONTRACTILITY AMELIORATING AGENT - Problem to Be Solved by the Invention: | 2017-02-09 |
| 20170035706 | DETRUSOR HYPERACTIVITY WITH IMPAIRED CONTRACTILITY AMELIORATING AGENT - Problem to Be Solved by the Invention: To providing a method for ameliorating DHIC. | 2017-02-09 |
| 20170035707 | Oral Dosage Forms of Ketamine - The present invention relates to an oral dosage form for administration of ketamine and a method of preparing an oral dosage form for administration of ketamine, preferably once or twice a day. | 2017-02-09 |
| 20170035708 | USE OF N-(4-TERT-BUTYLBENZYL)-3-CHLORO-N-[2-(4-CHLORO-3-ETHYL-PHENYL)-ETHY- L]-2-FLUORO-5-TRIFLUOROMETHYL-BENZAMIDE FOR THE TREATMENT OF EYE DISEASES - The present invention relates N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(4-chloro-3-ethyl-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benz-amide which is useful in the prevention, treatment, delaying progression and/or reduction of eye diseases, in particular wherein the eye diseases are intraocular neovascular diseases and its method of preventing, retarding and ameliorating eye diseases, in particular intraocular neovascular diseases. | 2017-02-09 |
| 20170035709 | METHODS OF TREATING PAIN OR FEVER USING PHARMACEUTICALLY ACTIVE ACETAMINOPHEN DIMERS LINKED THROUGH PHENOLIC HYDROXYL GROUPS - Provided herein are methods for treating pain such as acute or chronic pain or fever in subject without risking hepatotoxicity. The subject may be at risk of hepatotoxicity if administrated an acetaminophen monomer. The method includes administering a pharmaceutical composition containing an acetaminophen dimer compound, wherein the phenolic hydroxyl groups of two acetaminophen compounds are linked via an ethylene spacer. | 2017-02-09 |
| 20170035710 | SELECTIVE HISTONE DEACTYLASE 6 INHIBITORS - Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed. | 2017-02-09 |
| 20170035711 | PARASITE CONTROL AGENT FOR PARASITICIDE - A parasite-control or parasiticide agent that exhibits excellent effects of controlling or expelling parasites, particularly endoparasites and that can be used safely contains at least one selected from the group consisting of compounds represented by formula (I) and salts thereof as an active ingredient thereof | 2017-02-09 |
| 20170035712 | DOPAMINERGIC MIMETICS - A method is described for providing acute symptomatic relief to a subject with Parkinson's Disease (PD) or other CNS disorders resulting from dopamine deficiency in the brain comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide therapeutic benefit in such neurological disorders. Preferred materials produce a ketosis is such that the total concentration of acetoacetate and (R)-3-hydroxybutyrate in the blood of the subject is raised to between 0.1 and 30 mM. | 2017-02-09 |
| 20170035713 | SYNERGISTIC COMBINATIONS OF CAROTENOIDS AND POLYPHENOLS - The present invention provides a therapeutic composition comprising one or more polyphenols and one or more carotenoids selected from the group consisting of lutein, lycopene and beta-carotene. The invention also provides methods for inhibiting or reducing the production of superoxide ions, NO, TNF-alpha and/or PGE | 2017-02-09 |
| 20170035714 | Oral Dosage forms having a High Loading of a Gabapentin Prodrug - Sustained release oral dosage forms with a high loading of a gabapentin prodrug are disclosed. | 2017-02-09 |
| 20170035715 | TOPICAL ANALGESIC LOTION - Technologies are described for a formulation and production of a formulation. The methods may comprise depositing a non-steroidal anti-inflammatory drug (NSAID) compound into a chamber. The methods may comprise depositing a muscle relaxant into the chamber. The methods may comprise depositing a calcium channel blocker into the chamber. The methods may comprise depositing a general anesthetic into the chamber. The methods may comprise depositing a local anesthetic into the chamber. The methods may comprise milling and mixing the NSAID compound, the muscle relaxant, the calcium channel blocker, the general anesthetic, and the local anesthetic into a powder. The methods may comprise adding a solvent with the powder. The methods may comprise mixing the solvent with the powder to form a solution. The methods may comprise adding a base cream to the solution. The methods may comprise mixing the base cream and the solution to form the formulation. | 2017-02-09 |
| 20170035716 | METHOD OF USING SOLABEGRON - Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Methods of using the pharmaceutical combinations for the treatment of one or more systems associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are al so disclosed. | 2017-02-09 |
| 20170035717 | AMYLOID FIBER FORMATION LIMITER OR INHIBITOR - The object of the present invention is to provide a formulation with the effect of effectively suppressing or inhibiting amyloid fibril formation by the dissolution, elimination (discharge), etc. of amyloid fibril formation in vivo. | 2017-02-09 |
| 20170035718 | USE OF CILASTATIN TO REDUCE THE NEPHROTOXICITY OF DIFFERENT COMPOUNDS - Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts. The invention is based on the discovery that a great number of nephrotoxic compounds, including drugs, enter the cells of the proximal tubule through the cholesterol rafts, and that cilastatin is able to interfere with this transport mechanism, decreasing the nephrotoxicity of such compounds to a variable extent. The nephroprotective effect is common to compounds of different chemical nature and solubility and is specific for the kidney, causing no interference with the effects of nephrotoxic drugs having their targets in other organs. Therefore, administration of cilastatin allows for decreasing the nephrotoxic effects of different drugs without reducing their therapeutic effects. | 2017-02-09 |
| 20170035719 | EICOSAPENTAENOIC ACID (EPA) FORMULATIONS - Provided herein are compositions comprising eicosapentaenoic acid (EPA) and polar lipids (e.g., glycolipids and phospholipids), and which do not contain any docosahexaenoic acid (DHA) or esterified fatty acids. | 2017-02-09 |
| 20170035720 | Use of Derivatives of Polyunsaturated Fatty Acids as Medicaments - Use of polyunsaturated fatty acid derivatives as medicaments or functional foods. The present invention relates to the use of 1,2-fatty acid derivatives in the treatment or prevention of common diseases whose etiology is based on alterations (of any type) of the cell membrane lipids, for example, changes in levels, in the composition or in the structure of these lipids. In addition, for diseases in which the regulation of lipid composition and of the structure of the membranes (or proteins that interact with membranes) causes the reversion of pathological state. | 2017-02-09 |
| 20170035721 | COMPOSITION FOR PREVENTING OR IMPROVING PERIPHERAL NEUROPATHY - Compositions which contain an amino acid containing serine and a lipid containing a n-3 fatty acid are useful for the prophylaxis or improvement of peripheral neuropathy. | 2017-02-09 |
| 20170035722 | METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT ON STATIN THERAPY - In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof. | 2017-02-09 |
| 20170035723 | PHARMACEUTICAL COMPOSITIONS FOR INHIBITING ANTIBIOTIC-RESISTANT MICROORGANISMS AND USES THEREOF - This invention provides an antibiotic drug for inhibiting drug-resistant microorganisms. The antibiotic drug comprises Fmoc-Ala-OPfp, and not only has non-cytotoxic for normal human cell but also can inhibit drug-resistant microorganisms. | 2017-02-09 |
| 20170035724 | MAMMALIAN SIRT1 ACTIVATOR - A method for activating mammalian SIRT1 in a cell comprising: | 2017-02-09 |
| 20170035725 | MUSCLE ATROPHY INHIBITOR - An extract of | 2017-02-09 |
| 20170035726 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS - Epicatechins, Epicatechin Oligomers, or Thiolated Epicatechins are applied (A) directly to a genital wart in the form of a cream, ointment, paste or solution, (B) directly to the genital wart wherein such cream, ointment, paste or solution contains as an additional active ingredient a skin permeabilizing agent, (C) following electrosurgical resection or removal of the genital wart in such form of a cream, ointment, paste or solution, (D) following chemical resection or extirpation of the genital wart in such form, (E) following surgical resection or removal of the genital wart in such form, wherein said Epicatechins, Epicatechin Oligomers, or Thiolated Epicatechins both provide antiviral activity against multiple strains of human pappilomavirus (HPV) and promote healing following resection polymers contained in a vehicle. Disclosed are the compositions, therapeutical kits containing such composition, methods of treatment using such composition, and methods of enhancing the stability of such composition. | 2017-02-09 |
| 20170035727 | TREATMENT OR PREVENTION OF SEBORRHEIC KERATOSIS USING ARTEMISININ AND DERIVATIVES THEREOF - The invention relates to a method of treating or preventing seborrheic keratosis. The method comprises locally applying to a subject in need thereof artemisinin and/or one or more structurally related compounds. Also disclosed are topical formulations comprising artemisinin and/or one or more structurally related compounds. | 2017-02-09 |
| 20170035728 | Compositions for Improved Body Composition - A nutritional supplement is provided comprising alpha-lipoic acid and curcumin. The nutritional supplement may be used for reducing weight or reducing weight gain, for reducing fat or reducing fat gain, for reducing loss in lean mass or maintaining lean mass, or for reducing loss of appetite or for maintaining appetite. | 2017-02-09 |
| 20170035729 | PHARMACEUTICAL COMPOSITION FOR TREATING MIGRAINE - The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base. | 2017-02-09 |
| 20170035730 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS - The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease. | 2017-02-09 |
| 20170035731 | PYRROLIDINE-2, 5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS - Uses of compound of Formula I: | 2017-02-09 |
| 20170035732 | PATCH AND METHOD FOR PRODUCING THE SAME - A method for producing a patch comprising a support layer and an adhesive agent layer comprises: | 2017-02-09 |
| 20170035733 | PHARMACEUTICAL COMPOSITION COMPRISING LACOSAMIDE AND LEVETIRACETAM - The present application relates to a fixed dose combination comprising lacosamide and levetiracetam, as well as to dosage regimens including such fixed dose combinations. The fixed dose combinations are suitable for the oral or parenteral treatment of various diseases, including in particular epilepsy and/or epileptic seizures. | 2017-02-09 |
| 20170035734 | PAR4 INHIBITOR THERAPY FOR PATIENTS WITH PAR4 POLYMORPHISM - Disclosed herein are methods for determining whether a PAR4 inhibitor should be administered to a human subject, the methods comprising administering a PAR4 inhibitor to a subject determined to have a “G” allele for a single-nucleotide polymorphism (SNP) at rs773902, and not administering a PAR4 inhibitor to a subject determined to have an “A” allele for the SNP at rs773902. A genotyping assay can be used to determine the SNP. | 2017-02-09 |
| 20170035735 | Use Of Enoximone In The Treatment Of Atopic Immune-Related Disorders, In Pharmaceutical Composition As Well As In Pharmaceutical Preparation - The invention involves the use of compounds from the class of aroyl-2H-imidazol-2-ones such as enoximone or a pharmaceutically acceptable salt thereof for modulating the immune system involved in a topic and immune-related disorders. In particular, the invention involves the use of (1,3-dihydro-4-methyl-5-[4-(methylthio)benzoyl]-2H-imidazol-2-on) or a pharmaceutically acceptable salt thereof. The invention also involves a pharmaceutical composition including aroyl-2H-imidazol-2-on or a pharmaceutically acceptable salt thereof in an active quantity for the treatment of a topic and immune-related disorders, by modulating the immune system involved in a topic and immune-related disorders. Preference is especially given to a pharmaceutical composition in a dosage unit of 5, 10 or 20 mg, based on the quantity of the active ingredient. | 2017-02-09 |
| 20170035736 | Compositions and Methods Comprising a Compounded Composition - The present application relates to compounded compositions, methods of making compounded compositions, kits comprising compounded compositions, containers comprising compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions comprising an anti-fungal agent and methods of using a compounded composition to treat or prevent a fungal infection or a suspected fungal infection. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2017-02-09 |
| 20170035737 | TREATMENT OF BRCA1-DEFECTIVE CANCER OR RESISTANT CANCERS - Provided herein are methods of treating cancer in a subject, by administering COH29 ((N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide)). The methods of treating include treating a BRCA1-defective subject, a PARP1 inhibitor-resistant subject or a DNA-damaging anti-cancer agent resistant subject. The methods include treating cancer by administering COH29 and a DNA-damaging anti-cancer agent in a combined synergistic amount. | 2017-02-09 |
| 20170035738 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES - [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: | 2017-02-09 |
| 20170035739 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF AS FACTOR XIA/PLASMA - The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders. | 2017-02-09 |
| 20170035740 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTIBACTERIAL AGENTS - Pharmaceutical compositions comprising aztreonam or a pharmaceutically acceptable derivative, and a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed. (I) | 2017-02-09 |
| 20170035741 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OX- O-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID - Methods of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid are disclosed. Also provided are pharmaceutical compositions comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, and methods of treatment using such compositions. | 2017-02-09 |
| 20170035742 | DURABLE TREATMENT WITH 4-AMINOPYRIDINE IN PATIENTS WITH DEMYELINATION - Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as MS. | 2017-02-09 |
| 20170035743 | 2,5-Disubstituted-Pyridyl Nicotinic Ligands, and Methods of Use Thereof - Disclosed are heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. The compounds are useful for treating a mammal suffering from any one of a range of therapeutic indications, including Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism, trichotillomania, and hypothermia. | 2017-02-09 |
| 20170035744 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR - Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: | 2017-02-09 |
| 20170035745 | PHARMACEUTICAL COMBINATIONS OF DABIGATRAN AND PROTON PUMP INHIBITORS - This invention is a novel pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof in combination with a proton pump inhibitor for use in the antithrombotic treatment with preventing or reducing the risk of a gastrointestinal disorder. | 2017-02-09 |
| 20170035746 | Pancreatic Cancer Therapy and Diagnosis - The present invention provides novel cancer therapeutics for treating pancreatic cancer, and novel diagnostic methods for detecting chronic pancreatitis and pancreatic cancer. The invention pertains to antagonists of dopamine receptors that inhibit the growth of pancreatic cancer cells. The invention in particular offers new therapy options based on the inhibition of the activity or expression of dopamine receptor D2 (DRD2). Diagnostic methods of the invention comprise the detection of the expression of DRD2 in pancreatic tissue. Diagnostic kits are also comprised. | 2017-02-09 |
| 20170035747 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF - The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. | 2017-02-09 |
| 20170035748 | DOSAGE FORMS OF PALONOSETRON HYDROCHLORIDE HAVING IMPROVED STABILITY AND BIOAVAILABILITY - Provided are solid oral dosage forms of palonosetron hydrochloride, methods of using the dosage forms to treat emesis, and methods of making the dosage forms. The dosage forms have improved stability and bioavailability, and are preferably in the form of liquid filled capsules. | 2017-02-09 |
| 20170035749 | Liposomes Useful for Drug Delivery to the Brain - The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. The present invention also provides for the methods and kits for the delivery of liposomal compositions to the brain. | 2017-02-09 |
| 20170035750 | NEW ANTI-CLOSTRIDIUM COMPOUNDS - The present invention relates to compounds having a backbone structure for use as antibiotic, more specifically use against infections with Gram positive bacteria, preferably | 2017-02-09 |
| 20170035751 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases - The present invention provides a compound of Formula I or Formula II: | 2017-02-09 |
| 20170035752 | METHODS FOR PRODUCING ARIPIPRAZOLE SUSPENSION AND FREEZE-DRIED FORMULATION - Disclosed are a method for producing an aripiprazole suspension, wherein the aripiprazole has a mean particle size of 1 to 10 ?m, the method comprising the steps of: (a) combining bulk aripiprazole and a vehicle to form a primary suspension; (b) subjecting the primary suspension to first pulverization using e.g., a high shear pulverizing machine, a dispersion machine that applies shear force to a material to be processed, a colloid mill, an ultrasonic dispersion machine, or a high-pressure jet type emulsifying dispersion machine to form a secondary suspension; and (c) subjecting the secondary suspension to second pulverization using e.g., a high-pressure jet type emulsifying dispersion machine to form a sterile final suspension; and a method for producing a freeze-dried formulation from the aripiprazole suspension. | 2017-02-09 |
| 20170035753 | CONCENTRATED, INHALABLE CIPROFLOXACIN FORMULATION - A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions. | 2017-02-09 |
| 20170035754 | METHODS AND COMPOUNDS FOR PREVENTING OSTEOARTHRITIS - The present application relates to therapeutics and pharmaceutical compositions, their use and also methods for preventing post-traumatic osteoarthritis, early or late stage, using compounds which inhibit either, or both, AMPA and KA glutamate receptors (Glu Rs). | 2017-02-09 |
| 20170035755 | SYK INHIBITORS - The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: | 2017-02-09 |
| 20170035756 | METHODS OF BLOCKING THE CXCR-4/SDF-1 SIGNALING PATHWAY WITH INHIBITORS OF BRUTON'S TYROSINE KINASE - In some embodiments, the present invention relates to novel small molecule inhibitors that block the CXCR4-SDF-1 signaling pathway by directly inhibiting members of the Tec family of kinases, namely Bruton's tyrosine kinase (BTK), and their use in treating diseases in which pathogenesis is mediated by the CXCR4/SDF-1 signaling pathway. | 2017-02-09 |
| 20170035757 | Method of Optimizing the treatment of Proliferative Diseases Mediated by the Tyrosine Kinase Receptor KIT with Imatinib - The invention relates to a method of treating proliferative diseases mediated by the tyrosine kinase receptor KIT, in particular GIST, in a human patient population. | 2017-02-09 |
| 20170035758 | Medicinal Drug with Activity against Gram Positive Bacteria, Mycobacteria and Fungi - A medicinal drug is provided with activity against gram positive bacteria, mycobacteria and fungi characterized in that it is a compound of the class of pyrimidine derivatives of salicylic aldehyde and perhydropyrimidine-2,4,6-triones selected from a group consisting of tautomeric forms, salt forms, and a cyclic form of pyrylium salts, and with the general formula: | 2017-02-09 |
| 20170035759 | TREATMENT OF PARASITIC DISEASES USING KDAC INHIBITOR COMPOUNDS - Methods of using KDAC inhibitor compounds for the treatment of various parasitic diseases are described. | 2017-02-09 |
| 20170035760 | GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS - Disclosed are inhibitors of human galactokinase of formula (1) that are useful in treating or preventing a galactokinase mediated disease or disorder, e.g., galactosemia. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal. Formula (I). | 2017-02-09 |
| 20170035761 | CYTOTOXIC COMPOUNDS WHICH ARE INHIBITORS OF THE POLYMERISATION OF TUBULIN - The invention relates to compounds which are inhibitors of the polymerization of tubulin, to the methods for the production thereof, and to the uses of same. | 2017-02-09 |
| 20170035762 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 2017-02-09 |
| 20170035763 | SKIN BARRIER FUNCTION IMPROVING AGENT - [PROBLEM] The problem to be solved by the invention is to provide a novel pharmaceutical use of a JAK inhibitor. | 2017-02-09 |
| 20170035765 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION - The present invention is concerned with the treatment of Pulmonary Arterial Hypertension (PAH) by administering Paliperidone. The instant invention further relates to use of a pharmaceutical composition comprising Paliperidone, for the treatment of PAH. | 2017-02-09 |
| 20170035766 | IRAK INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same. | 2017-02-09 |
| 20170035767 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES - The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of intellectual disabilities. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of intellectual disabilities comprising a compound according to the invention and a pharmaceutically acceptable carrier. | 2017-02-09 |
| 20170035768 | NOVEL COMPOSITION FOR TREATMENT OF ESSENTIAL THROMBOCYTHEMIA - The present invention relates to a novel pharmaceutical composition free of gastric coating comprising anagrelide hydrochloride in combination with a non-pH dependent polymer and a pharmaceutically acceptable watersoluble acid and its use for the treatment of essential thrombocythemia. | 2017-02-09 |
| 20170035769 | NOVEL PYRAZOL DERIVATIVES - The invention relates to a compound of formula (I) | 2017-02-09 |
| 20170035771 | Compounds and Compositions for Ossification and Methods Related Thereto - The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement. | 2017-02-09 |
| 20170035772 | METHODS FOR TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER - The present invention provides a method of using arylpiperazine derivatives for treating attention deficit hyperactivity disorder (ADHD). The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative. | 2017-02-09 |
| 20170035773 | PREPARATION CONTAINING TETRACYCLIC COMPOUND AT HIGH DOSE - An improved solubility of a pharmaceutical composition or formulation containing a large amount of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile or a salt thereof can be achieved by forming granules of the compound or salt thereof and allowing the granules to be present together with a disintegrating agent. | 2017-02-09 |
| 20170035774 | APREPITANT ORAL LIQUID FORMULATIONS - A liquid pharmaceutical compositions comprising Aprepitant is preferably prepared as an oral suspension dosage form for the prevention and control of acute and delayed chemotherapy induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting. | 2017-02-09 |
| 20170035775 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS - The present invention provides compounds of Formula (I): | 2017-02-09 |
| 20170035776 | COMPOSITION FOR PREVENTING OR TREATING FATTY LIVER DISEASES - The present invention relates to a pharmaceutical composition for preventing or treating fatty liver diseases, containing (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]amine or a pharmaceutically acceptable salt thereof as active ingredients. (Tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]amine or a pharmaceutically acceptable salt thereof, according to the present invention, can effectively inhibit fatty liver, hepatitis and hepatic fibrosis and can be useful for preventing or treating NAFLD, and in particular, NASH. | 2017-02-09 |
| 20170035777 | LONG-ACTING POLYMERIC DELIVERY SYSTEMS - Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural). | 2017-02-09 |
| 20170035778 | FORMULATIONS AND USES FOR MICROPARTICLE DELIVERY OF METALLOPORPHYRINS - Formulations and methods of use thereof that relate to biocompatible delivery of stabilized porphyrin complexes are provided. Formulations may include microparticles comprising the porphyrin complex, wherein the porphyrin active agent is admixed or coated with a pharmaceutically acceptable stabilizer. | 2017-02-09 |
| 20170035779 | TOPICAL COMPOSITIONS COMPRISING BIMATOPROST AND METHODS FOR STIMULATING HAIR GROWTH THEREWITH - Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I | 2017-02-09 |
| 20170035780 | Combination of Azelastine and Fluticasone for Nasal Administration - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration. | 2017-02-09 |
| 20170035781 | 17-HYDROXYPROGESTERONE ESTER-CONTAINING ORAL COMPOSITIONS AND RELATED METHODS - The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier. | 2017-02-09 |
| 20170035782 | MODULATION OF INFLAMMATION USING PROGESTERONE METABOLITES - Methods for modulating inflammation using progesterone metabolites are disclosed. More particularly, methods of administering progesterone metabolites, 6β-hydroxyprogesterone (6β-OHP) and 16α-hydroxyprogesterone (16α-OHP) are disclosed for mitigating inflammation in various tissue types in the body. | 2017-02-09 |
| 20170035783 | COMPOSITION FOR THE PREVENTION AND THERAPY OF TUMOR DISEASES - The invention relates to a means of prevention and therapy of hormone-sensitive tumour tissue, especially for the prevention and/or inhibition of mammary carcinoma or prostate carcinoma. The composition according to the invention is characterised by comprising steroid hormones and aromatase inhibitors. This is preferably a triple combination of the steroid hormones oestriol (E3), progesterone and testosterone and an aromatase inhibitor. Another object of the invention is the use of the composition according to the invention for the manufacture of a drug for the prevention and therapy of hormone-sensitive tumours, preferably the mammary carcinoma or the prostate carcinoma. Areas of application of the invention are the pharmaceutical industry and the life sciences, especially medicine and medical technology, | 2017-02-09 |
| 20170035784 | COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE - The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions. | 2017-02-09 |
| 20170035785 | Compositions and Methods for the Treatment of Meibomian Gland Dysfunction - Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction. | 2017-02-09 |
| 20170035786 | METHODS FOR INHIBITING THE DEVELOPMENT, FORMATION AND/OR MATURATION OF BACTERIAL AND FUNGAL BIOFILMS - The present disclosure describes compositions and methods for inhibiting the development, formation and/or maturation of bacterial and fungal biofilms. The biofilm inhibiting compositions include non-steroidal anti-inflammatory drugs (NSAIDs) as APIs, and ethoxylated oil as a solubilizing agent. The ethoxylated oils employed within the biofilm inhibiting compositions includes between 9 and 24 ethoxylations/molecules. The NSAIDs agents within the biofilm inhibiting compositions inhibit the syntheses of prostaglandins by blocking the cyclooxygenase (COX) enzyme system due to the analgesic, anti-inflammatory, and antipyretic properties of the NSAIDs. The biofilm inhibiting compositions inhibit the cyclooxygenase isoenzymes required for prostaglandin formation, thereby preventing the colonization of fungi or bacteria as well as the formation of biofilms. | 2017-02-09 |
| 20170035787 | Fixed Dose Combination for Pain Relief Without Edema - Compositions and methods for individualized therapy of pain using a non-steroidal anti-inflammatory drug (NSAID) and an anti-hypertensive without inducing intolerable edema. Said methods comprise basing NSAID/anti-hypertensive dose on each patient's pharmacokinetic response to said NSAID. | 2017-02-09 |
